

**Participants with Severe Adverse Events**  
 (Incidence  $\geq 0\%$  in One or More Treatment Groups)  
 (ASaT Population)

	Placebo	Xanomeline Low Dose	Xanomeline High Dose
	n	n	n
Participants in population	86	84	84
with one or more severe AE	7	16	8
with no severe AE	79	68	76
cardiac disorders	3	0	1
atrial fibrillation	0	0	1
atrioventricular block second degree	1	0	0
myocardial infarction	2	0	0
gastrointestinal disorders	0	0	2
gastrointestinal haemorrhage	0	0	1
nausea	0	0	1
general disorders and administration site conditions	0	7	0
application site dermatitis	0	1	0
application site erythema	0	2	0
application site irritation	0	3	0
application site pruritus	0	1	0
application site warmth	0	1	0
sudden death	0	1	0

**Participants with Severe Adverse Events**  
**(Incidence  $\geq$  0% in One or More Treatment Groups)**  
**(ASaT Population)**

	Placebo	Xanomeline Low Dose	Xanomeline High Dose
	n	n	n
infections and infestations	0	1	0
nasopharyngitis	0	1	0
injury, poisoning and procedural complications	1	0	1
hip fracture	1	0	1
musculoskeletal and connective tissue disorders	1	1	0
arthritis	1	0	0
muscle spasms	0	1	0
neoplasms benign, malignant and unspecified (incl cysts and polyps)	0	1	1
colon cancer	0	1	0
prostate cancer	0	0	1
nervous system disorders	0	3	4
dizziness	0	0	1
headache	0	1	0
partial seizures with secondary generalisation	0	0	1
stupor	0	1	0
syncope	0	2	1
transient ischaemic attack	0	1	1

**Participants with Severe Adverse Events**  
**(Incidence  $\geq$  0% in One or More Treatment Groups)**  
**(ASaT Population)**

	Placebo	Xanomeline Low Dose	Xanomeline High Dose
	n	n	n
psychiatric disorders	1	1	0
agitation	0	1	0
completed suicide	1	0	0
reproductive system and breast disorders	1	0	0
benign prostatic hyperplasia	1	0	0
skin and subcutaneous tissue disorders	0	4	1
blister	0	1	0
pruritus	0	1	0
rash	0	1	1
skin irritation	0	1	0
This is footnote			

Source: [Study CDISCPILOT01: adam-adae]